260 related articles for article (PubMed ID: 27479883)
21. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
22. [New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma].
Czepczyński R; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J
Pol Arch Med Wewn; 2006 Sep; 116(3):853-60. PubMed ID: 18652278
[TBL] [Abstract][Full Text] [Related]
23. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC.
Artiko V; Afgan A; Petrović J; Radović B; Petrović N; Vlajković M; Šobić-Šaranović D; Obradović V
Nucl Med Rev Cent East Eur; 2016; 19(2):99-103. PubMed ID: 27479786
[TBL] [Abstract][Full Text] [Related]
25. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
[TBL] [Abstract][Full Text] [Related]
26. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
[TBL] [Abstract][Full Text] [Related]
27. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
Campennì A; Pignata SA; Baldari S
Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy.
Nocuń A; Chrapko B; Gołębiewska R; Stefaniak B; Czekajska-Chehab E
Nucl Med Commun; 2011 Jun; 32(6):522-9. PubMed ID: 21383640
[TBL] [Abstract][Full Text] [Related]
29. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
30. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.
Stokkel MP; Verkooijen RB; Smit JW
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):950-7. PubMed ID: 14991244
[TBL] [Abstract][Full Text] [Related]
31. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
32. (99m)Tc HYNIC-TOC imaging and 177Lu DOTA-octreotate treatment in non-iodine-concentrating dedifferentiated thyroid carcinoma metastases: an unusual alternative diagnosis.
Basu S; Joshi A
Clin Nucl Med; 2014 Jul; 39(7):632-4. PubMed ID: 24873792
[TBL] [Abstract][Full Text] [Related]
33. [99mTc Tetrofosmin in diagnosis of distant metastases from differentiated thyroid cancer].
Drac-Kaniewska J; Kozłowicz-Gudzińska I; Tomaszewicz-Kubasik H; Kaniewski M; Godlewska P; Czetwertyńska M; Chaładaj-Kujawska A
Wiad Lek; 2001; 54 Suppl 1():357-62. PubMed ID: 12182048
[TBL] [Abstract][Full Text] [Related]
34. Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a
Spanu A; Nuvoli S; Marongiu A; Gelo I; Mele L; Piras B; Madeddu G
BMC Cancer; 2020 Mar; 20(1):239. PubMed ID: 32197595
[TBL] [Abstract][Full Text] [Related]
35. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
37. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
39. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
40. Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma.
Valsamaki P; Gotzamani-Psarrakou A; Tsiouris S; Molyvda-Athanasopoulou E; Psarrakos K; Papantoniou V; Gerali S; Zerva C
Int J Cancer; 2006 Aug; 119(4):968-70. PubMed ID: 16550594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
